Skip to content

Understanding the Hype Cycle of GLP-1 Drugs

Every so often, healthcare discovers a miracle. Or at least the media does. Right now, with that miracle is the class of drugs known as GLP-1 agonists—medicines like Ozempic, Wegovy, and Mounjaro. If you follow the headlines, they promise massive weight loss, protection against heart disease, better metabolic health, and possibly benefits in areas as diverse as addiction and neurodegenerative disease.

To hear the hype, you would think these drugs would solve America’s obesity crisis and reshape the economics of healthcare. But anyone who has spent time in healthcare—or marketing—knows that innovation rarely travels in a straight line. It travels in hype cycles. And GLP-1 drugs are now deep into one.

The Breakthrough Phase

First, let’s acknowledge the obvious: these drugs represent a genuine scientific advance.

GLP-1 receptor agonists mimic hormones that regulate appetite and glucose metabolism. By slowing gastric emptying and increasing feelings of fullness, they help patients eat less. For people living with obesity or type 2 diabetes, the results can be significant.

Patients are losing meaningful amounts of weight. Blood sugar control improves. Some studies suggest cardiovascular benefits.

That is the breakthrough phase of the cycle: real science meeting a real medical need.

But breakthroughs attract attention—and attention attracts exaggeration.

When Medicine Becomes a Cultural Phenomenon

At some point the story jumped from medical journals to celebrity gossip. Suddenly, rumors surfaced that half of Hollywood was using Ozempic to lose weight. Media outlets began discussing a future in which obesity might be “solved.” Investors poured billions into companies like Novo Nordisk and Eli Lilly and Company, betting that GLP-1 drugs will dominate the pharmaceutical market for decades.

That’s when the hype cycle really took off. The narrative shifted from these drugs can help some patients lose weight to these drugs will transform society. Healthcare has seen this movie before.

What the Headlines Leave Out

The hype rarely includes the trade-offs.

GLP-1 drugs can cause significant side effects—nausea, vomiting, gastrointestinal distress, and other issues that make some patients abandon treatment. For others, the drugs simply do not work as well as advertised.

There is also the inconvenient reality that these medicines are not a one-time intervention. In many cases they require long-term use.

And when patients stop taking them, the weight often comes back.

That changes the narrative from a breakthrough treatment to something closer to lifelong metabolic management.

Then there’s the cost.

Even when insurance covers these drugs, access can be uneven. Without coverage, the price can easily reach hundreds—or even thousands—of dollars per month. For many patients, the miracle drug exists mostly in headlines.

The Distortions Created by Hype

Another predictable outcome of hype cycles is supply disruption.

Demand for drugs like Wegovy and Mounjaro surged so quickly that manufacturers struggled to keep up. In some cases, patients with diabetes—the original target population—had trouble filling prescriptions because of the explosion in demand for weight-loss products.

When a therapy becomes a cultural trend rather than a targeted treatment, such distortions are inevitable.

What Happens Next

If history is any guide, the GLP-1 story will eventually move into the next phase of the cycle: normalization.

The drugs will settle into a clearer role in clinical care. Some patients will benefit tremendously. Others will discontinue treatment because of side effects, cost, or lack of long-term results.

New competitors and new formulations will enter the market. Prices will likely fall over time. Physicians will become more selective about which patients truly benefit.

And eventually the headlines will move on to the next miracle.

What Pharma Marketers Are Getting Wrong

The biggest misunderstanding may actually be happening inside the pharma industry itself. Many pharma marketers appear to believe that the success of GLP-1 drugs is driven primarily by promotion.

It isn’t.

The demand explosion is being driven by something far more powerful: patient conversations happening online.

People struggling with obesity are sharing their experiences on social media, in forums, and in online communities. They are comparing results, side effects, dosing strategies, and even ways to obtain compounded versions of the drugs when supply runs short.

In other words, the real marketing engine behind GLP-1 drugs is social proof.

That matters because it exposes a blind spot in traditional pharma marketing. Television commercials and glossy patient websites may generate awareness, but they are not where most patients are forming their opinions about these drugs. Those decisions are increasingly shaped by what other patients say about them online.

Yet many pharmaceutical companies still treat these conversations as background noise rather than critical market intelligence.

The Real Lesson

GLP-1 drugs represent an important step forward in treating obesity and metabolic disease. But they are not magic.

Obesity is influenced by biology, behavior, environment, and economics. No single drug—no matter how effective—will solve it.

The real danger of hype cycles in healthcare is not excitement. Innovation should be exciting.

The danger is when expectations outrun reality.

Because when that happens, the people left dealing with the consequences are usually the patients.

Topics:

Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

Leave a Reply

Send this to a friend